JPWO2020047029A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020047029A5 JPWO2020047029A5 JP2021510860A JP2021510860A JPWO2020047029A5 JP WO2020047029 A5 JPWO2020047029 A5 JP WO2020047029A5 JP 2021510860 A JP2021510860 A JP 2021510860A JP 2021510860 A JP2021510860 A JP 2021510860A JP WO2020047029 A5 JPWO2020047029 A5 JP WO2020047029A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- composition
- rheumatoid arthritis
- interleukin
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 92
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 90
- 229940100601 interleukin-6 Drugs 0.000 claims description 87
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 61
- 102000004889 Interleukin-6 Human genes 0.000 claims description 56
- 108090001005 Interleukin-6 Proteins 0.000 claims description 56
- 239000000427 antigen Substances 0.000 claims description 49
- 108091007433 antigens Proteins 0.000 claims description 49
- 102000036639 antigens Human genes 0.000 claims description 49
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims description 33
- 108020003175 receptors Proteins 0.000 claims description 31
- 101710185757 Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 239000003435 antirheumatic agent Substances 0.000 claims description 13
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims description 13
- 229960002964 adalimumab Drugs 0.000 claims description 12
- 210000001503 joint Anatomy 0.000 claims description 12
- 229960000106 biosimilars Drugs 0.000 claims description 10
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229960000485 methotrexate Drugs 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 6
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims description 6
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 4
- 102100032752 C-reactive protein Human genes 0.000 claims description 4
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 4
- 230000009266 disease activity Effects 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 229950006348 sarilumab Drugs 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 2
- 238000012286 ELISA Assay Methods 0.000 claims description 2
- 108010008165 Etanercept Proteins 0.000 claims description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 2
- 102000015617 Janus Kinases Human genes 0.000 claims description 2
- 108010024121 Janus Kinases Proteins 0.000 claims description 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 239000004012 Tofacitinib Substances 0.000 claims description 2
- 102000013127 Vimentin Human genes 0.000 claims description 2
- 108010065472 Vimentin Proteins 0.000 claims description 2
- 229960003697 abatacept Drugs 0.000 claims description 2
- 230000003460 anti-nuclear Effects 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 229950000971 baricitinib Drugs 0.000 claims description 2
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 claims description 2
- 238000004820 blood count Methods 0.000 claims description 2
- 229960003115 certolizumab pegol Drugs 0.000 claims description 2
- 229950001565 clazakizumab Drugs 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 229960000403 etanercept Drugs 0.000 claims description 2
- 238000009093 first-line therapy Methods 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- 229960001743 golimumab Drugs 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229960000598 infliximab Drugs 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 229960000681 leflunomide Drugs 0.000 claims description 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 229940071643 prefilled syringe Drugs 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 238000004062 sedimentation Methods 0.000 claims description 2
- 238000009097 single-agent therapy Methods 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 2
- 229960001940 sulfasalazine Drugs 0.000 claims description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 2
- 238000011285 therapeutic regimen Methods 0.000 claims description 2
- 229960003989 tocilizumab Drugs 0.000 claims description 2
- 229960001350 tofacitinib Drugs 0.000 claims description 2
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 2
- 210000005048 vimentin Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 73
- 229950006094 sirukumab Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862724212P | 2018-08-29 | 2018-08-29 | |
| US62/724,212 | 2018-08-29 | ||
| US201862747301P | 2018-10-18 | 2018-10-18 | |
| US62/747,301 | 2018-10-18 | ||
| US201962798697P | 2019-01-30 | 2019-01-30 | |
| US62/798,697 | 2019-01-30 | ||
| US201962824399P | 2019-03-27 | 2019-03-27 | |
| US62/824,399 | 2019-03-27 | ||
| US201962856431P | 2019-06-03 | 2019-06-03 | |
| US62/856,431 | 2019-06-03 | ||
| US201962858443P | 2019-06-07 | 2019-06-07 | |
| US62/858,443 | 2019-06-07 | ||
| EP19192387 | 2019-08-19 | ||
| EP19192387.9 | 2019-08-19 | ||
| PCT/US2019/048460 WO2020047029A1 (en) | 2018-08-29 | 2019-08-28 | Methods and compositions for treating subjects having rheumatoid arthritis |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022502350A JP2022502350A (ja) | 2022-01-11 |
| JP2022502350A5 JP2022502350A5 (https=) | 2022-09-02 |
| JPWO2020047029A5 true JPWO2020047029A5 (https=) | 2022-09-02 |
| JP7504871B2 JP7504871B2 (ja) | 2024-06-24 |
Family
ID=67851236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510860A Active JP7504871B2 (ja) | 2018-08-29 | 2019-08-28 | 関節リウマチを有する対象を治療するための方法および組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11319375B2 (https=) |
| EP (1) | EP3843852A1 (https=) |
| JP (1) | JP7504871B2 (https=) |
| KR (1) | KR20210049871A (https=) |
| CN (1) | CN112955222A (https=) |
| AU (2) | AU2019329958B2 (https=) |
| BR (1) | BR112021003206A2 (https=) |
| CA (1) | CA3110891A1 (https=) |
| CL (1) | CL2021000483A1 (https=) |
| IL (1) | IL280824A (https=) |
| MA (1) | MA53481A (https=) |
| MX (2) | MX2021002422A (https=) |
| PH (1) | PH12021550416A1 (https=) |
| SG (1) | SG11202101674QA (https=) |
| TW (2) | TWI868074B (https=) |
| WO (1) | WO2020047029A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020261431A1 (en) | 2019-04-24 | 2021-12-09 | Regeneron Pharmaceuticals, Inc. | Methods of diagnosis and treatment of rheumatoid arthritis |
| FR3095698B1 (fr) * | 2019-05-03 | 2021-05-07 | Sinnovial | Procédé d’estimation de l’efficacité de traitement par un agent anti-CD20 chez un patient atteint de polyarthrite rhumatoïde et en réponse inadéquate a au moins une biothérapie |
| EP3980459A1 (en) | 2019-06-04 | 2022-04-13 | Sanofi Biotechnology | Compositions and methods for treating pain in subj ects with rheumatoid arthritis |
| IL298088A (en) * | 2020-05-26 | 2023-01-01 | Sanofi Biotechnology | The compositions containing an antibody against the interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using them |
| KR20230031015A (ko) * | 2021-08-26 | 2023-03-07 | 주식회사 이뮨메드 | 자가면역질환의 예방 또는 치료를 위한 항체의약품 |
| CN117138126B (zh) * | 2023-08-30 | 2024-04-09 | 江苏恰瑞生物科技有限公司 | 定向清除炎症因子il-6的过滤材料及过滤柱 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171840A (en) | 1988-01-22 | 1992-12-15 | Tadamitsu Kishimoto | Receptor protein for human B cell stimulatory factor-2 |
| US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| EP1097945B1 (en) | 1991-03-18 | 2007-07-04 | New York University | Monoclonal and chimeric antibody specific for human tumor necrosis factor |
| EP0628639B1 (en) | 1991-04-25 | 1999-06-23 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
| US5215534A (en) | 1991-12-02 | 1993-06-01 | Lawrence De Harde | Safety syringe system |
| KR100232688B1 (ko) | 1992-09-15 | 1999-12-01 | 스코트 쥐. 홀퀴스트 | 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물 |
| PT783893E (pt) | 1994-10-07 | 2012-05-24 | Chugai Pharmaceutical Co Ltd | Inibição do crescimento anormal das células sinoviais usando antagonistas de il-6 como componente ativo |
| ZA971600B (en) | 1996-02-26 | 1997-09-22 | Merck & Co Inc | Treatment of macular edema. |
| US6670373B1 (en) | 1999-10-07 | 2003-12-30 | Eli Lilly And Company | Compounds and method for inhibiting MRP1 |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CA2817619A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| EP2062916A3 (en) | 2003-04-09 | 2009-08-19 | Genentech, Inc. | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor |
| CN1989439B (zh) | 2004-05-06 | 2010-12-29 | 美国政府健康及人类服务部 | 治疗葡萄膜炎的方法以及组合物 |
| EA014226B1 (ru) | 2004-07-26 | 2010-10-29 | Байоджен Айдек Ма Инк. | Антитела к cd154, их фрагменты и способы применения антител и фрагментов |
| CN101326195B9 (zh) | 2005-12-13 | 2022-11-11 | 伊莱利利公司 | 抗il-17抗体 |
| US20080131374A1 (en) | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| FR2920033B1 (fr) | 2007-08-13 | 2014-08-22 | Snecma | Turbomachine avec diffuseur |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| JP4885308B2 (ja) | 2009-03-19 | 2012-02-29 | 中外製薬株式会社 | 改良された抗体分子を含有する製剤 |
| JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
| EP2464666B1 (en) * | 2009-07-15 | 2018-03-21 | Eva Kovacs-Benke | Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| KR20130065662A (ko) | 2010-05-07 | 2013-06-19 | 조마 테크놀로지 리미티드 | ⅠＬ-1β 관련 병태의 치료 방법 |
| US9427531B2 (en) | 2010-06-28 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Auto-injector |
| EP2670438A4 (en) | 2011-02-03 | 2015-05-20 | Santarus Inc | SELECTION AND TREATMENT OF PATIENTS |
| TWI568888B (zh) | 2011-09-15 | 2017-02-01 | 第諾拉工業公司 | 氣體擴散電極及其製法和電化電解池 |
| TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
| US9248242B2 (en) | 2012-04-20 | 2016-02-02 | Safety Syringes, Inc. | Anti-needle stick safety device for injection device |
| CA2922732A1 (en) * | 2013-09-03 | 2015-03-12 | L. Douglas GRAHAM | Treatment methods for rheumatoid arthritis |
| AU2014352801B2 (en) * | 2013-11-22 | 2020-05-28 | Regeneron Pharmaceuticals, Inc. | Compositions for the treatment of rheumatoid arthritis and methods of using same |
| WO2015116852A1 (en) * | 2014-01-29 | 2015-08-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating rheumatoid arthritis by administering an il-6r antibody |
| AU2015317905A1 (en) | 2014-09-16 | 2017-03-16 | Regeneron Pharmaceuticals, Inc. | Compositions for improving the health related quality of life of rheumatoid arthritis patients |
| IL319993A (en) | 2015-11-03 | 2025-06-01 | Sanofi Biotechnology | Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same |
| BR112018067851A2 (pt) | 2016-03-07 | 2019-02-05 | Regeneron Pharma | composições e métodos para o tratamento de artrite reumatoide |
| EP3216461A1 (en) * | 2016-03-07 | 2017-09-13 | Sanofi Biotechnology | Compositions and methods for treating rheumatoid arthritis |
-
2019
- 2019-08-28 AU AU2019329958A patent/AU2019329958B2/en active Active
- 2019-08-28 TW TW108130759A patent/TWI868074B/zh active
- 2019-08-28 BR BR112021003206-1A patent/BR112021003206A2/pt unknown
- 2019-08-28 JP JP2021510860A patent/JP7504871B2/ja active Active
- 2019-08-28 CN CN201980065880.1A patent/CN112955222A/zh active Pending
- 2019-08-28 WO PCT/US2019/048460 patent/WO2020047029A1/en not_active Ceased
- 2019-08-28 KR KR1020217008732A patent/KR20210049871A/ko not_active Ceased
- 2019-08-28 EP EP19763150.0A patent/EP3843852A1/en active Pending
- 2019-08-28 MA MA053481A patent/MA53481A/fr unknown
- 2019-08-28 MX MX2021002422A patent/MX2021002422A/es unknown
- 2019-08-28 CA CA3110891A patent/CA3110891A1/en active Pending
- 2019-08-28 US US16/553,338 patent/US11319375B2/en active Active
- 2019-08-28 SG SG11202101674QA patent/SG11202101674QA/en unknown
- 2019-08-28 TW TW113147810A patent/TW202532441A/zh unknown
-
2021
- 2021-02-11 IL IL280824A patent/IL280824A/en unknown
- 2021-02-25 CL CL2021000483A patent/CL2021000483A1/es unknown
- 2021-02-26 MX MX2025010592A patent/MX2025010592A/es unknown
- 2021-02-26 PH PH12021550416A patent/PH12021550416A1/en unknown
-
2022
- 2022-03-23 US US17/701,748 patent/US20230059376A1/en not_active Abandoned
-
2025
- 2025-05-09 AU AU2025203365A patent/AU2025203365A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6657089B2 (ja) | 関節リウマチを治療するための組成物およびこれを使用する方法 | |
| JP2022502350A5 (https=) | ||
| CA3116725C (en) | Secukinumab for use in the treatment of psoriatic arthritis | |
| JP2024069453A5 (https=) | ||
| Md Yusof et al. | Targeting interleukin-6 in rheumatoid arthritis | |
| JP7288927B2 (ja) | 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ－１７アンタゴニストの使用 | |
| Thompson et al. | Anti cytokine therapy in chronic inflammatory arthritis | |
| JP2018135373A (ja) | 関節リウマチを治療するための組成物およびこれを用いる方法 | |
| JP7145162B2 (ja) | 化膿性汗腺炎の処置 | |
| AU2016250388A1 (en) | Treatment for rheumatoid arthritis | |
| TWI868074B (zh) | 用來治療患有類風濕性關節炎之個體的方法及組成物 | |
| Gabay et al. | Biological agents in monotherapy for the treatment of rheumatoid arthritis | |
| Nishimoto et al. | Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study | |
| JPWO2020047029A5 (https=) | ||
| JP2020045351A (ja) | 関節リウマチを治療するための組成物およびこれを使用する方法 | |
| JP7841752B2 (ja) | 関節リウマチを有する対象における非炎症性疼痛を治療するための組成物および方法 | |
| Maria Luchetti et al. | Biologic therapy in inflammatory and immunomediated arthritis: safety profile | |
| RU2747193C2 (ru) | Композиции, содержащие антитела к il6r, для лечения увеита и макулярного отека, и способы их применения | |
| Favalli et al. | FRI0229 Survival on treatment of the second line biologic therapy: switch or swap strategy? | |
| Pamukcu et al. | Which anti-TNF is most effective for my patient? Which one should I choose? | |
| WO2025257781A1 (en) | Treatment of systemic sclerosis using anti-baff-r antibodies | |
| HK40110169A (en) | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients | |
| Saiki et al. | Successful extension of tocilizumab infusion intervals from 4 weeks to 5 or 6 weeks in 90% of rheumatoid arthritis patients with good response to 4-week intervals | |
| JP2024516019A (ja) | 抗ｂａｆｆｒ抗体を使用する全身性エリテマトーデスのための治療 | |
| ANTI | New developments in the pre-clinical phases of rheumatoid arthritis |